These studies provide the first description of the pharmacology of OGA inhibition required for reduction of tauopathy, identify decreases in CSF tau as a translatable biomarker of pathological tau reduction by OGA inhibition, and confirm direct O-GlcNAcylation of tau as the likely mechanism by which OGA inhibition reduces pathological tau. Here, MAPT is linked to tauopathy.